In this special edition of EAU Podcasts, experts met in person at the EAU Annual Congress (EAU24) to discuss the newest updates to the EAU Guidelines on muscle-invasive and metastatic bladder cancer (MIBC). 

Panel chair Prof. J.A. Witjes led the conversation with co-chair Assoc. Prof. A. Van Der Heijden and panel member Prof. R. Cathomas to cover additions to the local imaging recommendations, restaging and new tools, systemic reviews to the guidelines, and combination therapies.

In this special edition of EAU Podcasts, experts Prof. Paolo Gontero and Prof. Alexandra Masson-Lecomte met in person at the EAU Annual Congress (EAU24) to discuss the newest updates to the EAU Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma (UTUC).

Panel Chairs Prof. Paolo Gontero and Prof. Alexandra Masson-Lecomte cover points of change in the UTUC guidelines, including genetic testing recommendations, risk classifications, and treatment recommendations.

In 'Episode 3' of the series “What young urologists need to know", titled "Mentorship and peer support: Navigating urology together”, Prof. Prokar Dasgupta (GB) and Assoc. Prof.  Juan Luis Vásquez (DK) talk about the crucial role of mentorship and peer support in the field of urology.

They discuss how guidance from experienced mentors and collaboration among peers can enhance professional growth, clinical skills, and overall well-being in the challenging realm of urological practice. 

Whether it's navigating complex cases or advancing career trajectories, this episode offers invaluable insights for aspiring and established urologists alike, emphasising the power of mentorship and camaraderie in shaping successful medical careers.

Tune in to 'Episode 2' of the series “What young urologists need to know", titled "Academic - clinics balance: How to achieve it?", where Prof. Bhaskar Somani (GB) and Ass. Prof. Giorgio Gandaglia (IT) navigate the delicate equilibrium between academia and clinical practice in urology.

In their discussion they share insightful strategies and personal experiences on balancing research commitments with patient care responsibilities. Whether you're a seasoned practitioner or an aspiring academic, this podcast offers invaluable guidance on maintaining balance between advancing medical knowledge and delivering optimal healthcare outcomes.

Tune in to this enriching discussion that promises to inspire and inform! 

In 'Episode 1' of the series on "What young urologists need to know", segment 2 covers the topic of "Balancing the life of a young urologist". Dr. Thomas Tailly (BE) and Dr. Michiel Sedelaar (NL) offer a comprehensive exploration of the age-old question: Is it truly possible to strike a balance between work and well-being? 

Dr. Tailly and Dr. Sedelaar delve into the intricate interplay between work and well-being. Through their insightful discussion and evidence-based insights, you can gain ideas on how to achieve a harmonious balance between professional commitments and personal fulfilment. Tune in to learn some practical strategies to cope in today's fast-paced world of urology. 

In 'Episode 3', the final of the series on "Metastatic renal cell carcinoma", Dr. Andrea Mari (IT) talks with Dr. Chiara Ciccarese (IT) from the Medical Oncology Unit at Fondazione Policlinico Universitario A. Gemelli IRCCS, in Rome. Together they have an in-depth discussion on "Beyond first-line treatment strategies for metastatic renal cell carcinoma".

Dr. Mari and Dr. Ciccarese delve into recent advancements in managing mRCC, including therapeutic options, and their impact on patient care and outcomes. From targeted therapies to immunotherapies, they offer a comprehensive exploration of the evolving treatment landscape.

Tune in to this engaging and informative conversation with two distinguished experts at the forefront of cancer research and treatment.

In 'Episode 2' of the series on "Metastatic renal cell carcinoma", Dr. Andrea Mari (IT) talks to Dr. Laura Marandino (GB) about "The first-line treatment strategies for metastatic renal cell carcinoma".

Dr. Andrea Mari and Dr. Laura Marandino unravel the complexities of mRCC management, exploring the latest advancements, therapeutic options, and their implications for patient care. From targeted therapies to immunotherapies, they provide a comprehensive overview of the evolving treatment landscape.

Tune in as we navigate through this insightful conversation with two distinguished guests at the forefront of cancer research and treatment.

This podcast episode was recorded before ASCO GU 2024. Please note that information discussed may not reflect updates from the conference. We encourage listeners to verify the latest information independently.

UROONCO PCa associate editor Dr. Constance Thibault (FR) talks to Prof. Christophe Hennequin from Saint-Louis Hospital, France about the GETUG-AFU 18 trial results he presented at ASCO GU24 in San Francisco.

Prof. Hennequin shares details on the design of the study, followed by the trial results of long-term dose escalation (80 vs 70Gy) combined with long-term androgen deprivation in high-risk prostate cancer. 

For more details on this study, you can read this abstract on the UROONCO Prostate Cancer educational platform.

In 'Episode 1' of a series on "Metastatic renal cell carcinoma", Assist. Prof. Andrea Mari (IT) and Prof. Ketan Badani (US) discuss "The role of cytoreductive nephrectomy for metastatic renal cell carcinoma ".

Assist. Prof. Andrea Mari and Prof. Ketan Badani delve into the pivotal role of cytoreductive nephrectomy in the management of metastatic renal cell carcinoma (mRCC). They talk about the rationale behind this surgical intervention, its impact on patient outcomes, and the evolving landscape of treatment strategies in advanced kidney cancer.

Whether you're a healthcare professional or someone seeking insights into cutting-edge cancer therapies, this discussion promises to illuminate the complexities of renal cell carcinoma management.

In this podcast, UROONCO RCC chief editor Dr. Carmen Mir (ES) interviews Prof. Michael Hofman from the Peter MacCallum Cancer Centre, Australia, on the results of his study “First-in-human safety, imaging and dosimetry of [68Ga]Ga-DPI-4452, a novel CA IX-targeting peptide, in patients with clear cell renal cell carcinoma (ccRCC)”. 

Prof. Hofman discusses the data he presented at ASCO GU24 in San Francisco and suggests that these first-in-human findings with radiolabelled DPI-4452 are encouraging for the subsequent evaluation of treatment with [177Lu]Lu-DPI-4452.

[68Ga]Ga-DPI-4452 provides exceptional images in patients with ccRCC without clinically significant toxicity. Very high SUVs and tumour-to-background ratios suggest potential for use in both diagnostics and patient selection for therapy. The tumour retention and rapid elimination support potential of [177Lu]Lu-DPI-4452 radioligand therapy. 

For more details on this study, you can read the abstract on the UROONCO Kidney Cancer educational platform.